111 related articles for article (PubMed ID: 15738598)
1. [Biochemical bone resorption markers in children with osteosarcoma].
Ambroszkiewicz J; Gajewska J; Laskowska-Klita T; Woźniak W
Med Wieku Rozwoj; 2004; 8(2 Pt 1):225-33. PubMed ID: 15738598
[TBL] [Abstract][Full Text] [Related]
2. [Markers of bone formation in children with osteosarcoma].
Gajewska J; Ambroszkiewicz J; Rychlowska-Pruszynska M; Laskowska-Klita T
Med Wieku Rozwoj; 2004; 8(2 Pt 1):235-43. PubMed ID: 15738599
[TBL] [Abstract][Full Text] [Related]
3. [Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma].
Ambroszkiewicz J; Gajewska J; Klepacka T; Bilska K; Woźniak W; Laskowska-Klita T
Pol Merkur Lekarski; 2006 Oct; 21(124):330-4. PubMed ID: 17205770
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma.
Ambroszkiewicz J; Gajewska J; Klepacka T; Chełchowska M; Laskowska-Klita T; Woźniak W
Adv Med Sci; 2010; 55(2):266-72. PubMed ID: 21084254
[TBL] [Abstract][Full Text] [Related]
5. [Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria].
Ambroszkiewicz J; Gajewska J; Chełchowska M; Ołtarzewski M; Laskowska-Klita T; Nowacka M; Milanowski A
Pol Merkur Lekarski; 2008 Jul; 25(145):57-60. PubMed ID: 18839616
[TBL] [Abstract][Full Text] [Related]
6. Bone markers in the management of patients with skeletal metastases.
Demers LM
Cancer; 2003 Feb; 97(3 Suppl):874-9. PubMed ID: 12548589
[TBL] [Abstract][Full Text] [Related]
7. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
9. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers.
Uemura H; Yasui T; Kiyokawa M; Kuwahara A; Ikawa H; Matsuzaki T; Maegawa M; Furumoto H; Irahara M
J Endocrinol; 2002 Aug; 174(2):353-9. PubMed ID: 12176675
[TBL] [Abstract][Full Text] [Related]
10. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
Brown JM; Vessella RL; Kostenuik PJ; Dunstan CR; Lange PH; Corey E
Clin Cancer Res; 2001 Oct; 7(10):2977-83. PubMed ID: 11595685
[TBL] [Abstract][Full Text] [Related]
11. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
12. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report].
Markiewicz K; Zeman K; Kozar A; Gołebiowska-Wawrzyniak M
Med Wieku Rozwoj; 2011; 15(1):25-31. PubMed ID: 21786509
[TBL] [Abstract][Full Text] [Related]
14. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
17. Plasma proteome predicts chemotherapy response in osteosarcoma patients.
Li Y; Dang TA; Shen J; Hicks J; Chintagumpala M; Lau CC; Man TK
Oncol Rep; 2011 Feb; 25(2):303-14. PubMed ID: 21165584
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and C-telopeptide of type I collagen in Polish healthy children and adolescents.
Gajewska J; Ambroszkiewicz J; Laskowska-Klita T
Adv Med Sci; 2006; 51():269-72. PubMed ID: 17357324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
